CONGRESS GUIDE

ERS International Congress 2016
DETAILED PROGRAMME
TUESDAY 06 SEPTEMBER, 2016
Aims : Today, immunooncology has almost completely revolutionised the treatment of various cancer types, especially lung cancer.
Moreover, encouraging preliminary data are available for mesothelioma. These entities respond to PD-1 and PD-L1 inhibition. In addition,
more and more targeted agents for lung cancer therapy are becoming available: these agents go beyond the tyrosine kinase blockade of
mutated EGFR and rearranged ALK. Another marked advance is Next Generation Sequencing (NGS), which facilitates the detection of
many dozens of mutations at the same time. However, the provocative question from the clinical standpoint remains: is detailed molecular
testing essential for treating patients with these drugs?
Track(s) : Oncology
Tag(s) : Clinical
Target audience : Clinician, Fellow, Immunologist, Junior member, Oncologist, Pathologist, Pharmaceutical industry representative,
Public health official, Pulmonologist, Researcher, Resident, Respiratory physician, Scientist, Student, Thoracic surgeon
Chairs : Joanna Chorostowska-Wynimko (Warszawa, Poland), Thomas Wehler (Homburg/Saar, Germany)
13:00
13:22
13:44
Is PD1/PD-L1 Resting ready for clinical practice? Pro
Celine Mascaux (Marseille, France)
Is PD1/PD-L1 Resting ready for clinical practice? Con
Rainer G. Wiewrodt (Münster, Germany)
Is Next Generation Sequencing Resting (NGSR) ready for clinical practice? Pro
Joanna Chorostowska-Wynimko (Warszawa, Poland)
4464
4465
4466
14:06
Is Next Generation Sequencing Resting (NGSR) ready for clinical practice? Con
Thomas Wehler (Homburg/Saar, Germany)
Room K Session 623 13:00 - 14:30
ERS General Assembly and Council: ERS General Assembly Meeting
Chairs : Jørgen Vestbo (Manchester, United Kingdom)
Room ICC Capital Suite 7 Session 624 13:00 - 14:30
Educational forum: Recertification of respiratory professionals: current practice and the future
Aims : To discuss the upcoming trends and challenges in recertification for respiratory professionals; to learn from best practices in
different countries.
Target audience : Pulmonologist, Educationalist, Clinician, Epidemiologist, General practitioner, Fellow, Junior member, Nurse,
Oncologist, Paediatrician, Pathologist, Respiratory physician, Resident, Physiotherapist, Thoracic endoscopist, Thoracic surgeon, Sleep
specialist/technologist, Respiratory therapist
Chairs : Ildikó Horváth (Budapest, Hungary)
4467
13:00
13:20
Definition and importance
Carolin Sehlbach (Maastricht, Netherlands)
Recertification in practice across the world
Frank W.J.M. Smeenk (Eindhoven, Netherlands), Luis Pérez de Llano (Lugo, Spain), Akihito Yokoyama
(Kochi, Japan), Carey C. Thomson (Boston, United States of America), Jonathan Bennett (Leicester, United
Kingdom)
4468
4469
14:00
Panel discussion
Frank W.J.M. Smeenk (Eindhoven, Netherlands), Luis Pérez de Llano (Lugo, Spain), Akihito Yokoyama
(Kochi, Japan), Carey C. Thomson (Boston, United States of America), Jonathan Bennett (Leicester, United
Kingdom)
Room ICC Capital Suite 8 Session 625 13:00 - 14:00
Patient forum: Communicating the impact and risk of air pollution to respiratory patients
A joint ELF/ERS session
Aims : To look at the ways in which healthcare professionals can best relay information to respiratory patients about the many issues
surrounding air quality and lung health; to investigate the best way to communicate the dangers and the risks to make sure that patients are
well informed and ready to take the most appropriate action.
Tag(s) : Healthy Lungs for Life (HLfL)
Chairs : Jonathan Grigg (London, United Kingdom), Dan Smyth (Dundalk, Ireland)
4470
13:00
Communicating the impact and risk of air pollution to respiratory patients
(, ), Chris J. Griffiths (Cambridge, United Kingdom)
5506
293 26.08.2016